Trial Profile

A Multicenter, Randomized, Double-blind, Vehicle Controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 1% OPA-15406 Ointment to the Vehicle in Adult Patients With Atopic Dermatitis (Phase 3 Trial)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 15 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Oct 2021 Results published in the Journal of the American Academy of Dermatology
27 Sep 2021 According to a Ostuka Pharmaceutical Co., Ltd. media release, Moizerto Ointment (difamilast) has received manufacturing and marketing approval in Japan for the indication of adult and pediatric (two years of age and older) atopic dermatitis.
25 Apr 2021 Results assessing efficacy and safety of a topical difamilast ointment, in adult and pediatric patients with atopic dermatitis from two phase 3 studies (NCT0390897 & NCT03911401), presented at the American Academy of Dermatology Virtual Meeting Experience 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com